Clinical observation on the newly diagnosis of type 2 diabetes mellitus treated with pancreatic kininogenase combined with continuous subcutaneous insulin injection

To study the therapeutic effect of pancreatic kininogenase combined with continuous subcutaneous insulin injection in the newly diagnosis of type 2 diabetes

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1800015918

Enrollment

Unknown

Registered

2018-04-28

Start date

2018-05-01

Completion date

Unknown

Last updated

2018-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes

Interventions

1:CSII

2: pancreatic kininogenase combined with continuous subcutaneous insulin injection

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. newly diagnosed T2DM,according to the WHO1999 criteria; 2. HbA1c values >9.0% at the time of disease was diagnosed.

Exclusion criteria

Exclusion criteria: 1) Patients with severe cardiac insufficiency and blood system diseases; 2) Patients with glaucoma or increased Intraocular pressure; 3) Liver and renal insufficiency, Cr is 1.5 times higher than normal, and ALT is 2 times higher than the upper limit of normal value; 4) Patients with gastrointestinal ulcer Concord; 5) Patients with acute cardiac infarction or acute cerebrovascular accident; 6) Patients with chronic arterial occlusion treated with vasodilators(including Chinese medicine for blood circulation and blood stasis) within one week; 7) Patients selected for lower extremity vascular stent, bypass or radiofrequency ablation three months before selection; 8) Persons suffering from mental illness or unable to cooperate; 9) Pregnant women, nursing mothers and women of childbearing age who do not have access to safe contraception; 10) Malignant neoplasms.

Design outcomes

Primary

Measure	Time frame
MBG;MAGE;insulin dose;glucose standard time;	—

Countries

China

Contacts

Public ContactJianhua Ma

Nanjing First Hospital

majianhua196503@126.com+86 18951670116

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026